Key Highlights

  • Keros discontinued development of cibotercept (KER-012) after safety concerns identified in its Phase 2 TROPOS trial in pulmonary arterial hypertension.
  • The company will exclusively prioritize clinical advancement of KER-065, reporting initial topline results from a Phase 1 trial in healthy volunteers.
  • The discontinuation was accompanied by corporate restructuring and Leadership changes as part of a strategic realignment.
  • Keros develops treatments targeting the TGF-beta family of proteins, and its value now centers on KER-065 and the company's cash position.

Keros Therapeutics (NASDAQ:KROS) has undergone a wrenching reset, discontinuing development of a lead cardiopulmonary drug after safety concerns and restructuring around a different candidate. Understanding what the company is now focused on, and what it discontinued, is essential to assessing the shares.

Keros's story shifted dramatically in 2026, leaving investors to weigh whether the company's remaining asset and cash position offer a path forward.

A Discontinued Program and a Strategic Realignment

Keros announced topline data from its Phase 2 TROPOS trial of cibotercept (KER-012) in pulmonary arterial hypertension and, following safety concerns identified in that study, moved to discontinue cibotercept's development, accompanied by corporate restructuring and leadership changes as part of a strategic realignment. The company said it would exclusively prioritize the clinical advancement of KER-065, another candidate, and it reported initial topline results from a Phase 1 trial of KER-065 in healthy volunteers. Discontinuing a lead program after safety issues is a major setback that removes a key value driver, but concentrating resources on a remaining asset, together with the company's cash, can give a reset biotech a path forward.

Business and Financial Position

Keros develops treatments targeting the TGF-beta family of proteins, which play roles in blood, bone and other conditions, and its value now centers on KER-065 following the discontinuation of cibotercept. As a clinical-stage company, its worth is tied to the remaining pipeline and, importantly, to its cash position, which can be substantial for a company that had advanced multiple programs and raised capital.

Cash Cushion Meets an Early-Stage Reset

The key signals are progress and data from the KER-065 program, the company's cash position and Burn Rate after restructuring, and any strategic actions aimed at maximizing value. Investors will be monitoring clinical timelines, the effect of the leadership changes, and whether the company pursues additional pipeline or corporate options.

Keros's reset is a stark reminder of how quickly a clinical-stage biotech's value can change when a lead program fails on safety, and the company now must prove that KER-065 can justify a fresh thesis. The one potential source of downside support is cash: companies that had advanced multiple programs and raised Capital can retain a Balance Sheet that cushions the equity.